On the Record · Johnson & Johnson
Johnson & Johnson acquisitions, on the record
The businesses Johnson & Johnson bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
AbiomedWord for word“The Interventional Solutions franchise achieved sales of $6.4 billion in 2023, representing an increase of 47.7% from 2022, which includes sales from Abiomed acquired on December 22, 2022.” 10-K for 2023 | acquisition | December 22, 2022 | — |
Kenvue Inc.Word for word“On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the Kenvue Common Stock), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion.” 10-K for 2023 | divestiture | May 8, 2023 | net proceeds of $4.2 billion |
Intra-Cellular Therapies, Inc.Word for word“The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.5 billion which closed on April 2, 2025, and for general corporate purposes.” 10-K for 2025 | acquisition | April 2, 2025 | approximately $14.5 billion |
ShockwaveWord for word“(1) Acquired on May 31, 2024 * Percentage greater than 100% or not meaningful The Surgery franchise achieved sales of $10.1 billion in 2025, representing an increase of 3.0% from 2024.” 10-K for 2025 | acquisition | May 31, 2024 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2017-01-01 | $4.51 billion | — | $1.57 billion |
| 2017-12-31 | $35.15 billion | — | $8.46 billion |
| 2018-12-30 | $899 million | — | $403 million |
| 2019-12-29 | $5.81 billion | — | $3.28 billion |
| 2021-01-03 | $7.32 billion | — | $1.46 billion |
| 2022-01-02 | $60 million | — | $0 |
| 2023-01-01 | $17.65 billion | $0 | $11.06 billion |
| 2023-12-31 | $0 | $200 million | $0 |
| 2024-12-29 | $15.15 billion | — | $8.21 billion |
| 2025-12-28 | $17.5 billion | — | $3.49 billion |
Deal filings since 2016
- 2023-08-25 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-05-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-12-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-12-22 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2022-11-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-11-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-08-29 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-06-16 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-02-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Johnson & Johnson’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.